Do analysts prefer DOMH or CDXS?

Codexis has a consensus target price of $5.00, indicating a potential upside of 123.21%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Codexis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, DOMH or CDXS?

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dominari $123.10M 0.51 -$22.43M -$4.03 N/A Codexis $70.39M 2.89 -$43.97M -$0.37 N/A

Is DOMH or CDXS more profitable?

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Codexis -40.97% -68.09% -23.72%

Does the media refer more to DOMH or CDXS?

In the previous week, Dominari and Dominari both had 2 articles in the media. Codexis' average media sentiment score of 0.75 beat Dominari's score of 0.67 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dominari 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend DOMH or AGEN?

Agenus has a consensus target price of $30.00, indicating a potential upside of 498.80%. Given Agenus' stronger consensus rating and higher probable upside, analysts clearly believe Agenus is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Agenus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, DOMH or AGEN?

Agenus has lower revenue, but higher earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dominari $123.10M 0.51 -$22.43M -$4.03 N/A Agenus $114.20M 1.83 $120K $1.59 3.15

Is DOMH or AGEN more profitable?

Agenus has a net margin of 50.49% compared to Dominari's net margin of -31.37%. Agenus' return on equity of -31.66% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Agenus 50.49% -31.66% 42.71%

Does the media refer more to DOMH or AGEN?

In the previous week, Agenus had 35 more articles in the media than Dominari. MarketBeat recorded 37 mentions for Agenus and 2 mentions for Dominari. Dominari's average media sentiment score of 0.67 beat Agenus' score of 0.13 indicating that Dominari is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dominari 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 5 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral

Do analysts rate DOMH or FBIO?

Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 405.95%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is DOMH or FBIO more profitable?

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Fortress Biotech 193.12% 109.66% 45.56%

Is SGMO or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% Dominari -31.37% -206.20% -155.26%

Do analysts prefer CRIS or DOMH?

Curis currently has a consensus price target of $340.00, suggesting a potential upside of 7,243.41%. Given Curis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Curis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CRIS or DOMH?

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curis $9.44M 0.96 -$7.58M -$23.80 N/A Dominari $123.10M 0.51 -$22.43M -$4.03 N/A

Is CRIS or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Dominari -31.37% -206.20% -155.26%

Does the media favor CRIS or DOMH?

In the previous week, Curis and Curis both had 2 articles in the media. Curis' average media sentiment score of 1.18 beat Dominari's score of 0.67 indicating that Curis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dominari 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dominari (DOMH) Competitors

$2.76 -0.05 (-1.78%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$2.76 0.00 (0.00%)

As of 07/17/2026 05:54 PM Eastern

Compare

DOMH vs. CDXS, AGEN, FBIO, SGMO, and CRIS

Should you buy Dominari stock or one of its competitors? MarketBeat compares Dominari with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dominari include Codexis (CDXS), Agenus (AGEN), Fortress Biotech (FBIO), Sangamo Therapeutics (SGMO), and Curis (CRIS). These companies are all part of the "biotechnology" industry.

How does Dominari compare to Codexis?

Dominari (NASDAQ:DOMH) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.51	-$22.43M	-$4.03	N/A
Codexis	$70.39M	2.89	-$43.97M	-$0.37	N/A

In the previous week, Dominari and Dominari both had 2 articles in the media. Codexis' average media sentiment score of 0.75 beat Dominari's score of 0.67 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dominari	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Codexis	-40.97%	-68.09%	-23.72%

42.5% of Dominari shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 55.3% of Dominari shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dominari has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Codexis has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

Codexis has a consensus target price of $5.00, indicating a potential upside of 123.21%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Codexis beats Dominari on 10 of the 15 factors compared between the two stocks.

How does Dominari compare to Agenus?

Dominari (NASDAQ:DOMH) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, Agenus had 35 more articles in the media than Dominari. MarketBeat recorded 37 mentions for Agenus and 2 mentions for Dominari. Dominari's average media sentiment score of 0.67 beat Agenus' score of 0.13 indicating that Dominari is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dominari	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	5 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral

Agenus has a net margin of 50.49% compared to Dominari's net margin of -31.37%. Agenus' return on equity of -31.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Agenus	50.49%	-31.66%	42.71%

Agenus has a consensus target price of $30.00, indicating a potential upside of 498.80%. Given Agenus' stronger consensus rating and higher probable upside, analysts clearly believe Agenus is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

42.5% of Dominari shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 55.3% of Dominari shares are owned by company insiders. Comparatively, 6.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Agenus has lower revenue, but higher earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.51	-$22.43M	-$4.03	N/A
Agenus	$114.20M	1.83	$120K	$1.59	3.15

Dominari has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Agenus has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

Summary

Agenus beats Dominari on 13 of the 16 factors compared between the two stocks.

How does Dominari compare to Fortress Biotech?

Dominari (NASDAQ:DOMH) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

42.5% of Dominari shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 55.3% of Dominari shares are held by insiders. Comparatively, 28.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 405.95%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Fortress Biotech has lower revenue, but higher earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.51	-$22.43M	-$4.03	N/A
Fortress Biotech	$63.26M	1.76	$6.82M	$3.17	1.06

In the previous week, Dominari had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Dominari and 0 mentions for Fortress Biotech. Dominari's average media sentiment score of 0.67 beat Fortress Biotech's score of 0.00 indicating that Dominari is being referred to more favorably in the media.

Company	Overall Sentiment
Dominari	Positive
Fortress Biotech	Neutral

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Fortress Biotech	193.12%	109.66%	45.56%

Dominari has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Summary

Fortress Biotech beats Dominari on 12 of the 16 factors compared between the two stocks.

How does Dominari compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Dominari	-31.37%	-206.20%	-155.26%

Dominari has higher revenue and earnings than Sangamo Therapeutics. Dominari is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Dominari	$123.10M	0.51	-$22.43M	-$4.03	N/A

Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Dominari has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sangamo Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Dominari had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Dominari and 0 mentions for Sangamo Therapeutics. Dominari's average media sentiment score of 0.67 beat Sangamo Therapeutics' score of 0.00 indicating that Dominari is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Dominari	Positive

Summary

Sangamo Therapeutics beats Dominari on 9 of the 16 factors compared between the two stocks.

How does Dominari compare to Curis?

Curis (NASDAQ:CRIS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Dominari	-31.37%	-206.20%	-155.26%

Curis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the broader market. Comparatively, Dominari has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.96	-$7.58M	-$23.80	N/A
Dominari	$123.10M	0.51	-$22.43M	-$4.03	N/A

Curis currently has a consensus price target of $340.00, suggesting a potential upside of 7,243.41%. Given Curis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Curis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Curis and Curis both had 2 articles in the media. Curis' average media sentiment score of 1.18 beat Dominari's score of 0.67 indicating that Curis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dominari	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

30.0% of Curis shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 5.8% of Curis shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Curis beats Dominari on 9 of the 15 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOMH vs. The Competition

Export

Metric	Dominari	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$62.41M	$3.06B	$7.01B	$12.29B
Dividend Yield	N/A	2.05%	2.67%	9.35%
P/E Ratio	-0.68	20.17	27.25	23.90
Price / Sales	0.51	351.16	527.76	91.71
Price / Cash	N/A	57.12	29.05	48.09
Price / Book	0.64	4.26	10.70	6.18
Net Income	-$22.43M	$65.46M	$3.59B	$332.02M
7 Day Performance	-2.47%	-3.20%	-2.20%	-2.05%
1 Month Performance	-18.10%	0.70%	1.63%	-2.18%
1 Year Performance	-48.79%	19.10%	25.64%	17.67%

Dominari Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOMH Dominari	0.4948 of 5 stars	$2.76 -1.8%	N/A	-48.8%	$62.41M	$123.10M	N/A	4
CDXS Codexis	3.0244 of 5 stars	$2.60 -2.3%	$5.00 +92.3%	-20.6%	$241.79M	$70.39M	N/A	250	News Coverage
AGEN Agenus	2.7407 of 5 stars	$3.50 +2.6%	$23.00 +557.1%	-18.5%	$142M	$114.20M	2.20	440	Analyst Downgrade Analyst Revision
FBIO Fortress Biotech	2.0171 of 5 stars	$2.99 +1.4%	$17.00 +468.6%	+72.3%	$98.00M	$66.16M	0.94	170	Gap Down
SGMO Sangamo Therapeutics	1.0219 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DOMH) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dominari (DOMH) Competitors